CSIMarket Company Name, Ticker, Competitors, else..
 
Neurogene Inc   (NASDAQ: NGNE)
 
Price: $37.1900 $0.95 2.621%
Day's High: $37.189998626708984 Week Perf: -3.18 %
Day's Low: $ 35.31 30 Day Perf: 13.14 %
Volume (M): 30,326 52 Wk High: $ 43.66
Volume (M$): $ 0 52 Wk Avg: $25.69
Open: $35.80 52 Wk Low: $15.93



 Market Capitalization (Millions $) 830
 Shares Outstanding (Millions) 22
 Employees 131
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -99
 Cash Flow (TTM) (Millions $) 53
 Capital Exp. (TTM) (Millions $) 1

Business Description


The company is a clinical-stage biotechnology firm developing genetic medicines for rare neurological diseases that are not addressed by conventional gene therapy. It focuses on overcoming the limitations of current gene therapies to create a differentiated product portfolio targeting complex neurological conditions with high unmet medical needs.


   Company Address: 535 W 24th St. New York 10011 NY
   Company Phone Number: 508-3568   Stock Exchange / Ticker: NASDAQ NGNE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CNTA        0.8% 
CORT   -7.39%    
ROIV   -4.63%    
SPRO   -2.44%    
SRPT        12.26% 
TRDA   -9.78%    
• View Complete Report
   



Business Update

Neurogenes NGN-401 Gene Therapy for Rett Syndrome Enters Pivotal Clinical Trial,

Published Thu, Nov 6 2025 9:10 PM UTC

Neurogene Advances Gene Therapy for Rare Neurological Conditions: Pivotal Trial for Rett Syndrome Begins In a significant milestone for the field of gene therapy, Neurogene Inc., a clinical-stage company dedicated to developing transformative genetic medicines, has announced the dosing of the first participant in its Embolden registrational trial for NGN-401, a groundbreakin...
Business Update

Advancing Gene Therapy Neurogene Inc. Reports Second Quarter 2025 Financial Results and Development Milestones in the...

Published Tue, Aug 12 2025 9:16 AM UTC

: Neurogene Inc. has reported its financial performance for the second quarter of 2025, marked by significant advancements in its ongoing clinical programs, particularly concerning Rett syndrome. As a burgeoning leader in the domain of genetic medicine, Neurogene continues to make strides in addressing the unmet needs of patients suffering from rare neurological disorders....
Business Update

A Mission to Transform Neurological CareIn a bid to revolutionize the treatment landscape for ...

Published Fri, May 9 2025 6:20 PM UTC

Innovative Strides: Neurogene Reports Q1 2025 Financial Results & Progress on Rett Syndrome Gene Therapy A Mission to Transform Neurological Care In a bid to revolutionize the treatment landscape for rare neurological disorders, Neurogene Inc. (Nasdaq: NGNE), a trailblazing clinical-stage biotechnology firm, has released its financial results for the first quarter of 2025. ...
Business Update

Advancements in Gene Therapy Monitoring Neurogenes Commitment Amidst Financial Challenges

Published Tue, Apr 29 2025 5:57 AM UTC

Neurogene Inc. an innovative player within the realm of gene therapy, is poised to make significant strides in the management and treatment of rare complications associated with high-dose gene therapy. During the upcoming 28th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT), scheduled for May 13-17, 2025, in New Orleans, Neurogene will present its...
Business Update

Neurogene Inc. Pioneering Advances in Genetic Therapies for Rare Neurological Disorders Amidst Promising Clinical Tri...

Published Tue, Nov 19 2024 5:10 AM UTC

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates In an era where the convergence of cutting-edge science and innovative business models is reshaping the landscape of biotechnology, Neurogene Inc. (Nasdaq: NGNE) stands at the forefront, dedicated to transforming the lives of patients afflicted with rare neurological diseases through pione...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 3.49
PEG (TTM) -

Financial Strength Current
Quick Ratio 12.89
Working Capital Ratio 13.08
Leverage Ratio (MRQ) 0.11
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -4.59 $
Revenues (TTM) -
Cash Flow (TTM) 2.39 $
Cash 10.9 $
Book Value 10.66 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -752,962
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.